MDGL MADRIGAL PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1157601 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY92.8%
TTM net income YoY46.2%
TTM EPS YoY24.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-10.7%
Net margin-10.9%
FCF margin-11.8%
EBITDA margin-10.6%
Returns
ROE-24.8%
ROA-11.1%
ROIC (approx.)-21.6%
Asset turnover1.02x
Leverage & solvency
Liabilities / assets56.3%
Debt / equity0.54x
Current ratio3.05x
Interest coverage-4.75x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.1%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $958.40M | $180.13M |
| Cost of revenue | — | $6.23M |
| Gross profit | — | $173.90M |
| R&D expense | $388.52M | $236.72M |
| SG&A expense | $813.83M | $435.06M |
| Operating income | -$300.10M | -$497.88M |
| Interest expense | $22.31M | $14.67M |
| Pretax income | -$158.50M | -$465.90M |
| Income tax | $0 | $0 |
| Net income | -$288.28M | -$465.89M |
| EBITDA | -$298.59M | -$496.78M |
| EPS (basic) | -12.85 | -21.90 |
| EPS (diluted) | -12.85 | -21.90 |
| Weighted avg. shares (diluted) | 22.43M | 21.27M |
| Balance sheet | ||
| Cash & equivalents | $198.69M | $105.02M |
| Short-term investments | $784.87M | $826.23M |
| Receivables | $134.48M | $53.82M |
| Inventory | $74.84M | $34.07M |
| Current assets | $1.25B | $1.03B |
| PP&E, net | $1.50M | $2.19M |
| Intangibles | $7.38M | $4.73M |
| Total assets | $1.26B | $1.04B |
| Current liabilities | $310.29M | $169.28M |
| Long-term debt | $339.88M | $117.57M |
| Total debt | $339.88M | $117.57M |
| Total liabilities | $656.90M | $287.86M |
| Shareholders' equity | $602.69M | $754.38M |
| Net debt | $141.19M | $12.55M |
| Shares outstanding | 22.84M | 22.00M |
| Cash flow statement | ||
| Operating cash flow | -$189.55M | -$455.57M |
| Capital expenditure | $467,000 | $1.46M |
| Free cash flow | -$190.02M | -$457.03M |
| Investing cash flow | $32.32M | -$274.39M |
| Financing cash flow | $255.98M | $735.06M |
| Depreciation & amortization | $1.51M | $1.10M |
| Stock-based compensation | $98.13M | $79.88M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.